Section 35-7-1802 - Definitions(a) As used in this article: (i) "Eligible patient" means a person who has: (B) Considered all other treatment options currently approved by the United States food and drug administration;(C) Received a recommendation from a physician for an investigational drug, biological product or device;(D) Given written, informed consent for the use of the investigational drug, biological product or device or, if the patient is a minor or lacks the mental capacity to provide informed consent, a parent or legal guardian has given written informed consent on the patient's behalf; and(E) Documentation from a physician that the person meets the requirements of this paragraph.(ii) "Investigational drug, biological product or device" means a drug, biological product or device that has successfully completed phase one of a clinical trial but has not yet been approved for general use by the United States Food and Drug Administration and remains under investigation in a clinical trial;(iii) "Terminal illness" means a disease that, without life-sustaining procedures, will soon result in death or a state of permanent unconsciousness from which recovery is unlikely.Added by Laws 2015 , ch. 174, § 1, eff. 7/1/2015.